Kevin Kunzmann

Johnson & Johnson's pharmaceuticals company is discontiuing pursuits of triple-combination treatment JNJ-4178.

About one million US adults and adolescents live with uncontrolled, persistent asthma — despite there already being an intensive regimen of standard therapies. Dupilumab may be a missing piece to comprehensive treatment.

The answer could be found in tick saliva.

According to the company, several other US applications for use are still pending, and additional clinical trials for “advanced therapeutic applications” are scheduled.

Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of September 8.

The investigational drug for geographic atrophy in AMD patients would be treating a majorly unmet need — if it succeeds.

The funds supplement a $12 million base given to the same state programs in July.

Subcutaneous monoclonal antibodies could change the stagnant scope of migraine treatment.

Cleveland Clinic physicians weigh in on their best methods for maintaining a good doctor-patient relationship.

Researchers found in data of 1,868 people that women who inject drugs are at a 38% greater risk of contracting HCV than men who inject drugs.

It becomes only the second FDA-approved drug for the movement disorder, following valbenazine (Ingrezza) earlier this year.

The Section Head of Hepatology at the Cleveland Clinic discusses current issues in treating hepatitis, and what's still to come in possibly eradicating the disease.

Surveyed LGB adults also reported notably greater rates of heart conditions with more lesbian and bisexual women reporting strokes and heart attacks than heterosexual women, and more gay and bisexual men reporting chest pain related to heart disease than heterosexual men.

A human plasma-derived immunoglobulin, the rabies immune globulin (KEDRAB) will be launched by creator Kamada Ltd. and Kedrion Biopharma in the US in early 2018.

The Novartis mobile app aims to track the physical and cognitive condition of patients on a daily basis.

In at least one particular vaccine, the national rate of initial dose was greater than 80%. The rate to take the booster dose was less than 40%.

Despite similar differences in average age, years of education, and years since MS diagnosis, studied men had a significantly lower perception of their health than women, on average.

GOCOVRI becomes the first drug ever approved for LID in Parkinson's disease patients.

D-512 is an antioxidant combination drug that is the result of modified on-the-market receptor agonists.

Glucommander is now approved for various enhancements in its patient service capabilities.

The seizure-causing condition now inflicts at least 3.4 million US patients, according to the CDC.

Neurotoxin EB-001's fast treatment start-up and shorter duration could make for a different focal pain reliever.

The potential Hepatitis B adult vaccine has had a half-decade of rebuff to its drug application.

“This study tells us that the opioid epidemic has made people sicker and killed more people, in spite of all the care we can provide in the ICU, including mechanical ventilation, acute dialysis, life support and round-the-clock care."

Within a week of a Presidential committee tasked with overseeing the epidemic, a study has shown national addiction drug death rates are understated.

The FDA decision regarding Zelboraf’s approval for Erdheim-Chester disease with BRAF V6000 Mutations is expected by December 2017.

A majority patients over 65 years old studied suffered a worse quality of life when told informed of their diagnoses.

The CDC-based study sought to combat influenza epidemic risks with an earlier jump on outbreak detection.

The investigational hepatitis-B drug has been rejected for approval twice in the past 3 years, but creator Dynavax Technologies still hopes for an early 2018 US commercial release.

The fixed-dose combination therapy is an 8-week, once-daily treatment option for all HCV genotype diagnoses.